Drugs / CART-TM4SF1 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05673434 | Jan 2023 → Jul 2024 | digestive system neoplasm | Changhai Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-TM4SF1 cells | “The investigators have developed novel TM4SF1-targeting CAR T-cells (CART-TM4SF1 cells) for the treatment of digestive system tumors.” NCT05673434 ↗ |
| Action | Deplete | “These engineered T-cells can target and kill the TM4SF1-positive tumor cells in vitro or in mice.” NCT05673434 ↗ |
| Modality | Cell therapy | “The Chimeric Antigen Receptor T-cells (CAR-T) that target TM4SF1 has been generated in our good manufacturing practices (GMP) facility” NCT05673434 ↗ |
| Route | Intravenous | “Then they are transfused back to the patients intravenously.” NCT05673434 ↗ |
| Target | TM4SF1 | “TM4SF1-targeting CAR T-cells” NCT05673434 ↗ |